Table 1.
Demographics and clinical variables of patients with SJS/TEN from 2008 to 2021.
Variable | % (mean or count) n = 77 |
---|---|
Age (years old) | 6–93 (45) |
Menstrual status | |
Premenstrual | 4% (3) |
Menstruating | 45% (35) |
post-menstrual/hysterectomy | 43% (33) |
Sexual activity | |
Yes | 17% (13) |
No | 22% (17) |
Not specified | 63% (48) |
Diagnosis | |
SJS | 55% (42) |
TEN | 43% (33) |
Extent of vulvovaginal involvement | |
Vulvar involvement | 55% (42) |
Vaginal involvement | 39% (30) |
Gynecology consult | 43% (33) |
Vaginal treatment recommendations (a) | 70% (21) |
Dilator recommended | 70% (21) |
Dilator used | 67% (20) |
Steroid cream/ointment | 71% (30) |
No vulvar treatment recommendations + | 19% (8) |
Vulvar treatment recommendations (b) | 81% (34) |
Gauze only | 19% (5) |
Topical Steroid | 45% (19) |
Other | 36% (15) |
Menstrual suppression (c) | 49% (17) |
Antifungal | 17% (13) |
(a) recommendation for vaginal dilator of the patients with documented vaginal involvement (n = 30). (b) Vulvar treatment recommendations of the patients with vulvar involvement (n = 42). (c) menstrual suppression of menstruating patients (n = 35).